Control de las hiperlipemias en la práctica clínica

Goldstein, 2001, Familial hypercholesterolemia, 2863

Civeira, 2005, Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation, Arterioscler Thromb Vasc Biol, 25, 1960, 10.1161/01.ATV.0000177811.14176.2b

Alonso, 2002, Hipercolesterolemia familiar heterocigota en España, Med Clin (Barc), 118, 487, 10.1016/S0025-7753(02)72428-7

Hill, 1991, Genetic and environmental factors affecting the influence of coronary artery disease in heterozygous familial hypercholesterolemia, Arterioscler Thromb, 11, 290, 10.1161/01.ATV.11.2.290

Hobbs, 1992, Molecular genetics of the LDL receptor gene in familial hypercholesterolemia, Hum Mutat, 1, 445, 10.1002/humu.1380010602

2004, Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia, Atherosclerosis, 173, 55, 10.1016/j.atherosclerosis.2003.11.010

Tejedor, 2005, Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia, Clin Chem, 51, 1137, 10.1373/clinchem.2004.045203

Genest, 1992, Familial lipoprotein disorders in patients with premature coronary artery disease, Circulation, 85, 2025, 10.1161/01.CIR.85.6.2025

Veerkamp, 2002, Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families, Arterioscler Thromb Vasc Biol, 22, 274, 10.1161/hq0202.104059

Pajukanta, 1998, Linkage of familial combined hyperlipidemia to chromosome 1q21-q23, Nat Genet, 18, 369, 10.1038/ng0498-369

Plaza-Pérez, 2000, Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis, Rev Esp Cardiol, 53, 815

De Backer, 2003, Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European guidelines on cardiovascular disease prevention in clinical practice. Executive summary, Eur Heart J, 24, 1601, 10.1016/S0195-668X(03)00347-6

Mata, 1996, Effect of dietary fat saturation on LDL oxidation and monocyte adhesion to human endothelial cells in vitro, Arterioscler Thromb Vasc Biol, 16, 1347, 10.1161/01.ATV.16.11.1347

Fuentes, 2001, A Mediterranean NCEP-I diet improve endothelial function in hypercholesterolemic males, Ann Intern Med, 134, 1115, 10.7326/0003-4819-134-12-200106190-00011

Pérez-Jiménez, 2002, Protective effect of dietary monounsaturated fat on arteriosclerosis: beyond cholesterol, Atherosclerosis, 163, 385, 10.1016/S0021-9150(02)00033-3

2002, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3

LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461

Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583

Smilde, 2001, Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial, Lancet, 357, 577, 10.1016/S0140-6736(00)04053-8

Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis, JAMA, 291, 1071, 10.1001/jama.291.9.1071

Akira, 2000, Discovery and development of the statins, 35

Alonso, 2005, Benefits and risks assessment of simvastatin in familial hypercholesterolaemia, Expert Opin Drug Saf, 4, 171, 10.1517/14740338.4.2.171

De Angelis, 2004, The influence of statin characteristics on their safety and tolerability, Int J Clin Pract, 58, 945, 10.1111/j.1368-5031.2004.00355.x

Davignon, 2004, The cardioprotective effects of statins, Curr Atheroscler Rep, 6, 27, 10.1007/s11883-004-0113-7

Liao, 2002, Isoprenoids as mediators of the biological effects of statins, J Clin Invest, 110, 285, 10.1172/JCI0216421

Transon, 1996, In vitro comparative inhibition profiles of major human drug metabolising P450 isoenzyes (CYP2C9, CYO2D6 and CYP3A4) by HMG-CoA reductase inhibitors, Eur J Clin Pharmacol, 50, 209, 10.1007/s002280050094

Davidson, 2001, Safety profiles for HMG-CoA reductase inhibitors, Drugs, 61, 1917, 10.2165/00003495-200161020-00005

Dujovne, 2002, Side effects of statins: hepatitis versus «transaminitis » - myositis versus «CPKitis», Am J Cardiol, 89, 1411, 10.1016/S0002-9149(02)02356-1

Thompson, 2003, Statin-associated myopathy, JAMA, 289, 1681, 10.1001/jama.289.13.1681

Bays, 1998, Drug interactions of lipid-altering drugs, Drug Saf, 1998, 355, 10.2165/00002018-199819050-00003

Prueksaritanont, 2002, Mechanistic studies on metabolic interactions between gemfibrozil and statins, J Pharmacol Exp Ther, 301, 1042, 10.1124/jpet.301.3.1042

Ballantyne, 2003, Possible differences between fibrates in pharmacokinetic interaction with statins, Arch Intern Med, 163, 2394, 10.1001/archinte.163.19.2394

Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomised controlled trial, JAMA, 285, 1585, 10.1001/jama.285.12.1585

Staels, 1998, Mechanisms of action of fibrates on lipid and lipoprotein metabolism, Circulation, 98, 2088, 10.1161/01.CIR.98.19.2088

Poulter, 1999, The impact of micronised fenofibrate on lipid subfractions and on reaching HDL target levels in 7098 patients with dyslipidemia, Br J Cardiol, 6, 682

Chinetti-Gbaguidi, 2005, Pleiotropic effects of fibrates, Curr Atheroscler Rep, 7, 396, 10.1007/s11883-005-0053-x

1978, A cooperative Trial in the Primary Prevention of Ischaemic Heart Disease using Clofibrate, Br Heart J, 40, 1069, 10.1136/hrt.40.10.1069

Sudhop, 2002, Inhibition of intestinal cholesterol absorption by ezetimibe in humans, Circulation, 106, 1943, 10.1161/01.CIR.0000034044.95911.DC

García-Calvo, 2005, The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1), Proc Natl Acad Sci USA, 102, 8132, 10.1073/pnas.0500269102

Stein, 2001, Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor, Eur Heart J, 3, 11, 10.1016/S1520-765X(01)90107-5

1984, JAMA, 251, 351, 10.1001/jama.1984.03340270029025

Sampson, 1999, Hyperlipidemia and combination drug therapy, 1213

Ellen, 1998, Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hiperlipidemia, Am J Cardiol, 81, B60, 10.1016/S0002-9149(98)00040-X

Thompson, 2003, LDL-apheresis, Atherosclerosis, 167, 1, 10.1016/S0021-9150(02)00251-4

De Jongh, 2002, Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomised, double-blind, placebo-controlled trial with simvastatin, Circulation, 106, 2231, 10.1161/01.CIR.0000035247.42888.82